HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data...
” NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 ” ” First regulatory filing for fruquintinib for use in...
Hutchmed (China) Limited (Hutchmed) announces that the supplemental New Drug Application (sNDA) for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mesenchymal epithelial transition factor (MET) exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration (NMPA). If approved, the new label indication for savolitinib will be expanded to include treatment-naive patients in China.
” Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients ” ” If approved, would...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the...
Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA„¢ (fruquintinib) Sovleplenib for ITP accepted for...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:‹HCM; HKEX:‹13) today announces that data from FRUTIGA,...
Inmagene Exercises Option to Obtain Worldwide License for IMG-007 and IMG-004
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the...